NR4A1 and melanoma: To validate NR4A1 as the primary molecular target of NR-V04 in the TME, we inoculated B16F10 melanoma tumors in NR4A1−/− mice and found that NR-V04 failed to inhibit B16F10 in these mice (Fig. 7 D).